Andreessen Horowitz-backed startup lands $200M for AI-based drug discovery
Genesis Therapeutics, a startup using artificial intelligence to design small molecule drugs, has raised $200 million in Series B financing — one of the largest rounds for an AI-focused biotech this year.
The round is being co-led by Andreessen Horowitz (a16z) Bio + Health and an anonymous life science investor. The Burlingame, CA-based company, which previously struck partnerships with Eli Lilly and Genentech, will use the money to further develop its generative and predictive AI technologies, expand its pipeline, and move its first computer-generated drugs into clinical studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.